本文選題：腫瘤免疫治療 + 免疫檢查點(diǎn)抑制劑��； 參考：《中國新藥雜志》2017年23期

【摘要】：腫瘤細(xì)胞可表達(dá)一些免疫檢查點(diǎn)分子,以逃避免疫系統(tǒng)的識別和攻擊。最近幾年,以程序性死亡因子(PD-1/PD-L1)和細(xì)胞毒T淋巴細(xì)胞抗原4(CTLA-4)為靶點(diǎn)的免疫檢查點(diǎn)抑制劑陸續(xù)獲FDA批準(zhǔn)上市。雖然有些患者經(jīng)以上藥物治療后出現(xiàn)完全緩解或生存期延長,但尚存在較大比例的患者并未從中獲益,而聯(lián)合用藥成為克服這一局限的有效方式。派姆單抗與化療聯(lián)用后因其出色的表現(xiàn),已成為非小細(xì)胞肺癌的一線治療方式。伊匹單抗與納武單抗在黑色素瘤中聯(lián)用較納武單抗單用的客觀緩解率顯著提高,成為黑色素瘤的一線治療選擇。除了以上獲批的幾種聯(lián)用方案,大量免疫檢查點(diǎn)抑制劑與化療、靶向治療、疫苗、放療、免疫調(diào)節(jié)劑及其他治療方式等聯(lián)合用藥的臨床研究正在開展,以期為臨床聯(lián)合用藥提供參考和依據(jù)。
[Abstract]:Tumor cells can express some immune checkpoint molecules to escape the recognition and attack of the immune system. In recent years, immunocheckpoint inhibitors targeting PD-1 / PD-L1 and cytotoxic T lymphocyte antigen 4CTLA-4) have been approved by FDA. Although some patients had complete remission or prolonged survival after the treatment of the above drugs, there was still a large proportion of patients who did not benefit from it, and combined use of drugs became an effective way to overcome this limitation. Pam monoclonal antibody combined with chemotherapy has become a first-line treatment for non-small cell lung cancer due to its excellent performance. The objective remission rate of combined use of ipiumab and navumab in melanoma was significantly higher than that of Navelumab and became the first line treatment option for melanoma. In addition to the several combination schemes approved above, a large number of clinical studies of immunocheckpoint inhibitors combined with chemotherapy, targeted therapy, vaccines, radiotherapy, immunomodulators and other treatment methods are under way. In order to provide reference and basis for clinical combined use of drugs.
【作者單位】： 首都醫(yī)科大學(xué)附屬北京朝陽醫(yī)院藥事部;
【基金】：國家自然科學(xué)基金資助項(xiàng)目(81703611) 北京市自然科學(xué)基金資助項(xiàng)目(7164262)
【分類號】：R730.5
，

本文編號：1864359